Adjunctive Intravitreal moxifloxacin and ranibizumab in the Management of Intraocular Tuberculoma.
Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic ATT and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration.
Authors
- Nehali Sureshchandra Pant
- Jyotirmay Biswas
Institutions
- Sankara Nethralaya (IN)
Publication Details
- Journal
- Retinal Cases & Brief Reports
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1097/icb.0000000000001857
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00